A novel controlled release formulation for the anticancer drug paclitaxel (Taxol®): PLGA nanoparticles containing vitamin E TPGS

Journal of Controlled Release

Volumn 86, Issue 1, 2003, Pages 33-48

  Mu, L ^a   Feng, S S ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Biodegradable polymer; d Tocopheryl polyethylene glycol 1000 succinate; Drug delivery; Emulsifier; Surfactant stabiliser; Taxol

Indexed keywords

ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; CREMOPHOR; EMULSIFYING AGENT; NANOPARTICLE; PACLITAXEL; POLYMER; TOCOFERSOLAN; ALPHA TOCOPHERYL POLYETHYLENE GLYCOL SUCCINATE; ALPHA-TOCOPHERYL POLYETHYLENE GLYCOL SUCCINATE; DRUG DERIVATIVE; LACTIC ACID; MACROGOL DERIVATIVE; POLYGLYCOLIC ACID; POLYLACTIC ACID POLYGLYCOLIC ACID COPOLYMER; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ADJUVANT THERAPY; ARTICLE; ATOMIC FORCE MICROSCOPY; CHEMOTHERAPY; CONTROLLED RELEASE FORMULATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; ENCAPSULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; LIGHT SCATTERING; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SOLVENT EXTRACTION; THERMOGRAPHY; X RAY PHOTOELECTRON SPECTROSCOPY; CHEMISTRY; DELAYED RELEASE FORMULATION; METHODOLOGY; NANOTECHNOLOGY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; LACTIC ACID; NANOTECHNOLOGY; PACLITAXEL; POLYETHYLENE GLYCOLS; POLYGLYCOLIC ACID; POLYMERS; VITAMIN E;

EID: 0037426719     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(02)00320-6     Document Type: Article

References (36)

1. Yeh M.K., Davis S.S., Coombes A.G.A. Improving protein delivery from microparticles using blends of poly (D,l lactide-co-glycolide) and poly (ethylene oxide)-poly (propylene oxide) copolymers. Pharm. Res. 13:1996;1693-1698.
2. Jalil R., Nixon J.R. Biodegradable poly (lactic acid) and poly (lactide-co-glycolide) microcapsules: problems associated with preparative techniques and release properties. J. Microencapsul. 7:1990;297-325.
3. Brannon-Peppas L. Recent advances in the use of biodegradable microparticles and nanoparticles in controlled drug delivery. Int. J. Pharm. 116:1995;1-9.
4. Maincent P., Le Verge R., Sado P., Couvreur P., Devissaguet J.P. Deposition kinetics and oral bioavailability of vincamin-loaded poly-alkyl cyanoacrylate nanoparticles. J. Pharm. Sci. 75:1986;955-958.
5. Zeltner T.B., Sweeney T.D., Skornik W.A., Feldman H.A., Brain J.D. Retention and clearance of 0.9-μm particles inhaled by hamsters during rest or exercise. J. Appl. Physiol. 70:1991;1137-1145.
6. Cappel M.J., Kreuter J. Effect of nanoparticles on transdermal drug delivery. J. Microencapsul. 8:1991;369-374.
7. Couvreur P., Tulkens P., Roland M., Trouet A., Speiser P. Nanocapsules: a new type of lysosomotropic carrier. FEBS Lett. 84:(2):1977;323-326.
8. Astier A., Doat B., Ferrer M.-J., Benoit G., Fleury J., Rolland A., Leverge R. Enhancement of adriamycin antitumor activity by its binding with an intracellular sustained-release form, polymethacrylate nanospheres, in U-937 cells. Cancer Res. 48:1988;1835-1841.
9. Labhasetwar V., Song C., Levy R.J. Nanoparticle drug delivery system for restenosis. Adv. Drug Deliv. Rev. 24:1997;63-85.
10. Beck P., Kreuter J., Reszka R., Fichtner I. Influence of polybutylcyanoacrylate nanoparticles and liposomes on the efficacy and toxicity of the anticancer drug mitoxantrone in murine tumour models. J. Microencapsul. 10:1993;101-114.
11. Simeonova M., Ilarionova M., Ivanova T., Konstantinov C., Todorov D. Nanoparticles as drug carriers for vinblastine. Acute toxicity of vinblastine in a free form and associated to polybutylcyanoacrylate nanoparticles. Acta Physiol. Pharmacol. Bulg. 17:1991;43-49.
12. Bennis S., Chapey C., Couvreur P., Robert J. Enhanced cytotoxicity of doxorubicin encapsulated in polyisohexylcyanoacrylate nanospheres against multidrug-resistant tumour cells in culture. Eur. J. Cancer. 30A:1994;89-93.
13. Verdun C., Brasseur F., Vranokx H., Couvreur P., Roland M. Tissue distribution of doxorubicin associated with polyisohexylcyanoacrylate nanoparticles. Cancer Chemother. Pharmacol. 26:1990;13-18.
14. Jain R.A. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials. 21:2000;2475-2490.
15. Johansen P., Men Y., Merkle H.P., Gander B. Revisiting PLA/PLGA microspheres: an analysis of their potential in parenteral vaccination. Eur. J. Pharm. Biopharm. 50:2000;129-146.
16. Wu X.S. Preparation, characterization, and drug delivery applications of microspheres based on biodegradable lactic/glycolic acid polymers. Wise D.L., et al. Encyclopedic Handbook of Biomaterials and Bioengineering. 1995;1151-1200 Marcel Dekker, New York.
17. Arshady R. Preparation of biodegradable microspheres and microcapsules: 2. Polylactides and related polyesters. J. Controlled Release. 17:1991;1-22.
18. Singla A.K., Alka G., Deepika A. Paclitaxel and its formulations. Int. J. Pharm. 235:(1-2):2002;179-192.
19. Tatou E., Mossiat C., Maupoil V., Gabrielle F., David M., Rochette L. Effects of cyclosporin and cremophor on working rat heart and incidence of myocardial lipid peroxidation. Pharmacology. 52:1996;1-7.
20. Dorr R.T. Pharmacology and toxicology of Cremophor EL diluent. Ann. Pharmacother. 28:1994;S11-S14.
21. Fjallskog M.L., Frii L., Bergh J. Is cremophor, solvent for paclitaxel, cytotoxic? Lancet. 342:1993;876.
22. Webster L., Linsenmeyer M., Millward M., Morton C., Bishop J., Woodcock D. Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype. J. Natl. Cancer Inst. 85:1993;1685-1690.
23. Mankad P., Spatenka J., Slavik Z., Oneil G., Chester A., Yacoub M. Acute effects of cyclosporine and cremophor EL on endothelial function and vascular smooth-muscle in the isolated rat-heart. Cardiovasc. Drug Ther. 6:1992;77-83.
24. Kongshaug M., Cheng L.S., Moan J., Rimington C. Interaction of Cremophor-EL with human plasma. Int. J. Biochem. 23:1991;473-478.
25. Mu L., Feng S.S. Vitamin E TPGS used as emulsifier in the solvent evaporation/extraction technique for fabrication of polymeric nanospheres for controlled release of paclitaxel (Taxol®). J. Controlled Release. 80:(1-3):2002;129-144.
26. Jeffery H., Davis S.S., Ohagan D.T. The preparation and characterization of poly(lactide-co-glycolide) microparticles. 1. Oil-in-water emulsion solvent evaporation. Int. J. Pharm. 77:(2-3):1991;169-175.
27. Scholes P.D., Coombes A.G.A., Illum L., Davis S.S., Vert M., Davies M.C. The preparation of sub-200 nm poly(lactide-co-glycolyde) microspheres for site-specific drug delivery. J. Controlled Release. 25:1993;145-153.
28. Beck L.R., Cowsar D.R., Lewis D.H., Cosgrove R.J., Riddle C.T., Lowry S.L., Epperly T. A new long-acting injectable microcapsule system for the administration of progesterone. Fertil. Steril. 31:(5):1979;545-551.
29. Wang Y.M., Sato H., Adachi I., Horikoshi I. Preparation and characterization of poly (lactic-co-glycolic acid) microspheres for targeted delivery of a novel anticancer agent, Taxol. Chem. Pharm. Bull. 44:1996;1935-1940.
30. Konan Y.N., Gurny R., Allemann E. Preparation and characterization of sterile and freeze-dried sub-200 nm nanoparticles. Int. J. Pharm. 233:2002;239-252.
31. Murakami H., Kawashima Y., Niwa T., Hino T., Takeuchi H., Kobayashi M. Influence of the degrees of hydrolyzation and polymerization of poly(vinylalcohol) on the preparation and properties of poly(DL-lactide-co-glycolide) nanoparticle. Int. J. Pharm. 149:1997;43-49.
32. Murakami H., Kobayashi M., Takeuchi H., Kawashima Y. Preparation of poly (DL-lactide-co-glycolide) nanoparticles by modified spontaneous emulsification solvent diffusion method. Int. J. Pharm. 187:1999;143-152.
33. Vitamin E TPGS, Properties and Applications, Eastman, USA, Publication EFC-226A, October 1998.
34. Curvier C., Roblot-Treupel L., Millot J.M., Lizard G., Chevillard S., Manfait M., Couvreur P., Poupon M.F. Doxorubicin-loaded nanospheres bypass tumour cell multidrug resistance. Biochem. Pharmacol. 44:1992;509-517.
35. Verdun C., Brasseur F., Vranckx H., Couvreur P., Roland M. Tissue distribution of doxorubicin associated with polyisohexylcyanoacrylate nanoparticles. Cancer Chemother. Pharmacol. 26:1990;13-18.
36. Holland S.J., Tighe B.J. Biodegradable Polymers. Garderton D., Jones T. Adv. Pharmaceutical Science. Vol. 6:1992;101-164 Academic Press, New York.